Well more good news for Novo Nordisk as the company released data from their PIONEER 5 a phase 3a trail for the oral version of semaglutide which per a company issued press release:
“The trial achieved its primary objective according to the primary statistical approach by demonstrating statistically significant and superior reductions in HbA1c with oral semaglutide compared to placebo at week 26. Furthermore, people treated with oral semaglutide achieved statistically significant and superior reductions in body weight compared to placebo at week 26.”
Now this is not the first nor will it be the last study we have seen . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.